Jump to main content
Jump to site search

Issue 6, 2013
Previous Article Next Article

Cerium oxide caged metal chelator: anti-aggregation and anti-oxidation integrated H2O2-responsive controlled drug release for potential Alzheimer's disease treatment

Author affiliations

Abstract

Metal ions play important roles in Aβ aggregate deposition and neurotoxicity which involves the formation of reactive oxygen species (ROS). Oxidative stress and metal dysregulation have been considered as therapeutic targets for AD. Herein, a novel double delivery platform has been presented by integrated anti-aggregation property of metal chelators and anti-oxidation property of CeO2NPs in one system for Alzheimer's disease treatment. Compared with metal chelators or CeO2NPs alone, a synergistic effect is observed in our H2O2-responsive controlled release system. So far, there is no report to use CeO2NP as both capping and antioxidant agent for AD therapy. By taking advantage of good biocompatibility, high selectivity toward toxic metal ions, and their ability to cross the blood–brain barrier (BBB), the two-in-one bifunctional nanoparticles can effectively inhibit Aβ aggregate formation, decrease cellular ROS and protect cells from Aβ-related toxicity.

Graphical abstract: Cerium oxide caged metal chelator: anti-aggregation and anti-oxidation integrated H2O2-responsive controlled drug release for potential Alzheimer's disease treatment

Back to tab navigation

Supplementary files

Article information


Submitted
13 Mar 2013
Accepted
03 Apr 2013
First published
04 Apr 2013

Chem. Sci., 2013,4, 2536-2542
Article type
Edge Article

Cerium oxide caged metal chelator: anti-aggregation and anti-oxidation integrated H2O2-responsive controlled drug release for potential Alzheimer's disease treatment

M. Li, P. Shi, C. Xu, J. Ren and X. Qu, Chem. Sci., 2013, 4, 2536
DOI: 10.1039/C3SC50697E

Social activity

Search articles by author

Spotlight

Advertisements